Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The ETS factor TEL2 is a hematopoietic oncoprotein.

Cintia Carella1, Mark Potter, Jacqueline Bonten

  • 1Department of Genetics and Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Blood
|October 20, 2005
PubMed
Summary

The TEL2/ETV7 oncogene promotes cell proliferation and can cause myeloproliferative disease. Leukemic transformation driven by TEL2 requires secondary mutations, highlighting its complex role in oncogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid Decoupled Electrochemical Reduction of CO<sub>2</sub> to Syngas.

ChemSusChem·2026
Same author

Bactericidal Action and <i>in Vitro</i> Immunomodulatory Effects of Ozone on Methicillin-Resistant <i>Staphylococcus Aureus</i>.

Frontiers in bioscience (Elite edition)·2026
Same author

Intracellular trafficking and nuclear compartmentalization of AAV gene delivery.

Molecular therapy. Advances·2026
Same author

Transdifferentiation of endothelial progenitor cells into rhabdomyosarcoma defined by hedgehog signaling competence.

Cell reports·2026
Same author

Identification of breakpoint regions and single nucleotide variations of RHD hybrid alleles by long-read sequencing.

Vox sanguinis·2026
Same author

AAV2 Crosslinks Actin Filaments: Implications for AAV Gene Therapy Vector Design.

bioRxiv : the preprint server for biology·2026

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • TEL2/ETV7 shares homology with TEL/ETV6, a transcription factor implicated in leukemia.
  • TEL2 and TEL exhibit opposing effects on cell proliferation and differentiation.
  • TEL2 is expressed in the hematopoietic system and its upregulation is observed in some leukemia patients.

Purpose of the Study:

  • To investigate the oncogenic potential of TEL2 in vivo.
  • To determine if secondary mutations are required for TEL2-induced leukemogenesis.
  • To elucidate the role of TEL2 in hematopoietic malignancies.

Main Methods:

  • Forced expression of TEL2 in mouse bone marrow.
  • Induction of secondary mutations using N-ethyl-N-nitrosourea (ENU).

Related Experiment Videos

  • Monitoring disease onset, progression, and type in transplanted mice.

    • Main Results:

    • Forced TEL2 expression alone induced myeloproliferative disease with long latency.
    • ENU treatment significantly accelerated disease onset.
    • While myeloid disease was observed, all mice ultimately succumbed to T-cell lymphoma, indicating a requirement for secondary mutations.

    Conclusions:

    • TEL2 is identified as a bona fide oncogene.
    • Leukemic transformation driven by TEL2 is dependent on the acquisition of secondary mutations.
    • TEL2's oncogenic activity is context-dependent and requires cooperating genetic events.